GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications

Key Takeaways GEHC received FDA approval to expand Vizamyl's label for beta-amyloid PET imaging and quantification. GE HealthCare can now use Vizamyl to monitor response to anti-amyloid therapies and diagnose Alzheimer's. GEHC expects broader Vizamyl use to support earlier diagnosis and more personalized treatment decisions.GE HealthCare Technologies Inc. (GEHC) has received the FDA’s approval for an updated label for its positron emission tomography (PET) imaging agent Vizamyl (flutemetamol F 18 injectio ...